整理 | GLP1减重宝典内容团队 2026年2月9日，杭州糖吉医疗科技股份有限公司正式向香港联合交易所提交上市申请，计划在港交所主板挂牌上市。本次上市的联席保荐人为 工银国际与财通国际。糖吉医疗是一家专注于医疗器械研发、制造与商业化的医疗科技公司，业务涉及医疗器械与相关耗材，并通过多个全资 或控股子公司协同推动产业化布局。 赛道与市场规模 根据招股书，糖吉医疗所处的赛道为代谢性疾病相关的医疗健康领域。代谢性疾病包括肥胖、超重、2型糖尿病、代谢相关脂肪性肝炎 （MASH）等，这些慢性疾病已成为全球医疗系统的沉重负担。弗若斯特沙利文等第三方研究报告显示，仅糖尿病一项，2021年全球相关死亡 人数约670万，中国约140万，对应的医疗支出分别为9,660亿美元和1,650亿美元。随着人口老龄化、生活方式变化以及疾病筛查率的提升，代 谢性疾病的医疗需求持续扩展，为医疗器械及解决方案提供了巨大的市场空间。 市场展望 企业发展与产品介绍 糖吉医疗成立于2016年，成立以来致力于医疗器械研发与产业化，逐步在中国及海外市场布局。目前，公司通过多家境内外子公司承担研发、 制造及区域化商业推进职能，包括衢州吉康医疗、天津糖吉数 ...

Core Viewpoint - Hangzhou Tangji Medical Technology Co., Ltd. has officially submitted its listing application to the Hong Kong Stock Exchange, aiming for a main board listing, with ICBC International and Caitong International as joint sponsors [2]. Industry and Market Size - Tangji Medical operates in the medical health sector related to metabolic diseases, which are among the heaviest burdens on global healthcare systems, including obesity, overweight, type 2 diabetes, and metabolic-associated fatty liver disease (MASH) [5]. - In 2021, approximately 6.7 million deaths globally were attributed to diabetes, with around 1.4 million in China, corresponding to medical expenditures of $966 billion and $165 billion, respectively. The demand for medical services related to metabolic diseases is expected to continue growing due to aging populations, lifestyle changes, and increased disease screening rates [8]. Company Overview - Founded in 2016, Tangji Medical focuses on the research and commercialization of medical devices. The company has established multiple wholly-owned or controlling subsidiaries to drive its industrial layout through collaborative efforts [4][13]. - The organizational structure reflects a typical R&D-driven model, with business operations not centralized under a single entity but rather distributed across various entities to enhance regional and phase-specific business development [13]. Product Introduction - Tangji Medical's product line is centered around medical devices, with a systematic classification based on specific application scenarios. The company has developed multiple product lines that cover different niche applications, with some products already in commercialization or registration stages [18]. - The gastric bypass stent system, a key product, utilizes a minimally invasive approach to reduce sugar and fat absorption, showing an average weight loss of 9 kg over three months and significant improvements in metabolic disease-related blood indicators [20]. Financial and Stage Assessment - Tangji Medical is currently not profitable, primarily due to accumulated tax losses and ongoing R&D expenditures, which are characteristic of early-stage medical device companies [21]. - The company is positioned more as a long-term player focused on chronic disease and metabolic health needs rather than a short-term performance-driven IPO case [22]. Future Outlook - The company's ability to gain further recognition in the capital market will depend on the successful market launch and performance of its core products [23].

Core Viewpoint - AI-powered diagnostic and monitoring devices are increasingly becoming the preferred choice for medical institutions in the Yangtze River Delta region, reflecting a trend towards digitalization and smart integration in the medical device industry [1][2]. Group 1: Evaluation and Trends - The "Yangtze River Delta New Excellent Domestic Medical Devices Recommendation" evaluation received submissions from 88 companies and 200 products, resulting in 96 recommended products and 59 nominated products after multiple rounds of expert reviews [2]. - The evaluation focuses on products manufactured in China after January 1, 2020, that have obtained domestic medical device registration certificates [2]. - Notable products include advanced imaging devices from leading domestic manufacturers, such as Mindray's photoacoustic imaging ultrasound diagnostic system and Neusoft's photon-counting CT [2]. Group 2: Industry Evolution - Medical devices are evolving from "auxiliary tools" to "decision partners," and from "generic products" to "personalized services," with a growing preference for imaging diagnostic devices that offer scientific and precise quantitative methods [2]. - The evaluation criteria emphasize the technical sophistication of products, including performance parameters, clinical validation, and market acceptance [3]. - The results of the evaluation will be published to assist medical institutions in adopting and approving relevant products [3].

Core Viewpoint - The article discusses the challenges of weight management and the phenomenon of weight regain after dieting, emphasizing the need for innovative solutions in the weight loss industry to combat this issue [1][2][6]. Group 1: Weight Management Initiatives - The National Health Commission of China has launched a three-year "Weight Management Year" initiative aimed at reducing weight and controlling chronic diseases [1]. - The concept of "metabolic memory" explains why individuals often regain weight after losing it, as the body tends to remember previous weight levels [2][6]. Group 2: Current Market Dynamics - The weight loss market is seeing significant sales, with drugs like semaglutide generating annual revenues of $28.3 billion [3]. - Major pharmaceutical companies, including Novo Nordisk and Eli Lilly, are focusing on developing new mechanisms and improving existing products to address muscle loss and weight regain during weight loss [2][10]. Group 3: Challenges in Weight Loss - Many weight loss methods lead to muscle loss, which can decrease the basal metabolic rate and exacerbate weight regain after stopping treatment [10]. - A study published in the Journal of the American Medical Association indicated that participants who stopped taking the weight loss drug tirzepatide regained an average of 14% of their lost weight within a year [8]. Group 4: Innovative Solutions and Research - Companies are exploring new drug targets and combination therapies to enhance weight loss while preserving muscle mass [10][11]. - The UK company NodThera is investigating an anti-inflammatory approach to weight loss, which has attracted interest from major players like Novo Nordisk [11]. Group 5: Long-term Weight Management Strategies - Experts recommend sustainable lifestyle changes, including balanced diets and regular exercise, as more effective long-term strategies for weight management compared to quick fixes [12][13]. - A comprehensive approach to weight management may involve a treatment cycle lasting over 20 months, focusing on identifying causes of obesity and designing personalized weight loss strategies [12].

近日， 糖吉医疗 顺利完成 近亿元 C轮融资 。此次融资由 朗玛峰创投 、 衢州绿石基金 两方共同参与，资金将赋能糖吉医疗加速在中国及国际市场的推广步伐、 推进注册临床试验进程、建设生产产线、扩大生产规模等多个关键领域，极大地推进其商业化进程，为糖吉医疗在代谢病治疗领域的征途上注入强劲动力。 # 公司介绍 糖吉医疗成立于2016年，总部位于浙江省杭州市，是一家专注于代谢病治疗领域的创新型医疗器械公司。公司致力于通过消化道介入技术开发创新的治疗方案，以 解决肥胖症、非酒精性脂肪肝炎（NASH）等代谢性疾病。凭借其全球首创的胃转流支架系统，糖吉医疗在代谢病治疗领域取得了显著的行业地位，并获得了国内 外市场的广泛关注。 产品与技术介绍 糖吉医疗的核心技术基于"物理性隔绝肠道能量吸收"和"重塑肠道微生态"的科学原理，开发了全球首个肠道介入治疗肥胖症的三类医疗器械—— 胃转流支架系统 。 市场表现： 2024年初，胃转流支架系统获得中国国家药品监督管理局的批准，并于同年10月获得美国食品药品监督管理局（FDA）的"突破性器械"认定。此外，该 产品还获得了印尼医疗器械注册证，成功进入东南亚市场。 糖吉医疗还推出了肥胖症指 ...